Bromfenac

This page contains recent news articles, when available, and an overview of Bromfenac but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

�?��?��?�得日本�?�壽術後眼部發炎眼藥水�?��?�銷售權  -  20 Oct 2008
...(中央社記者潘智義�?�北2008年10月20日)�?��?�生技醫藥(4120)今天宣布與日本�?�壽製藥株�?會社簽訂治療術後眼部發炎眼藥水--Bromfenac yam天空新�?�,

生技：具防禦特質，麥格�?�看好，懷特�?�?��?�大漲5%  -  20 Oct 2008
...�?�?旗下產�?骨寶簽定技術授權主�?�?款，分階段�?�得150�?�美元授權金；�?��?�與日本�?�壽製藥株�?會社簽訂治療術後眼部發炎眼藥水--Bromfenac 中網�?�財,

Financings Roundup  -  Sep 26, 2008
The company is advancing its pipeline products, including a Phase III-stage program with Xibrom (bromfenac ophthalmic solution) for pain and inflammation in TMCnet

Primary pterygium excision involves ‘peeling-off’ technique  -  Oct 9, 2008
Also, an NSAID is used, namely Xibrom 0.09% (bromfenac ophthalmic solution, Ista Pharmaceuticals), twice daily. For globe protection, the patient is asked OSN SuperSite (subscription),

DXEK exchanges corneal disc after failed penetrating keratoplasty  Sep 10, 2008
Also, a nonsteroidal anti-inflammatory drug is used preoperatively, namely Xibrom 0.09% (bromfenac ophthalmic solution, Ista Pharmaceuticals) twice daily,OSN SuperSite (subscription),

The National Medicinal Drug Policy and the FDA Model  -  Jul 28, 2008
Top selling anti-inflammatory drug bromfenac and antihistamine terfenadine were withdrawn between 1997 and 1998 after being prescribed to millions. The Island (subscription),

Automated anterior lamellar keratoplasty combines dermoid excision ...  -  Jul 9, 2008
Also, Xibrom 0.09% (bromfenac ophthalmic solution, Ista Pharmaceuticals), a nonsteroidal anti-inflammatory drug, is used preoperatively twice a day, OSN SuperSite (subscription),

Gene therapy offers hope for hereditary blindness  -  May 23, 2008
The other 30 patients received Xibrom (bromfenac ophthalmic solution, Ista Pharmaceuticals) 0.09% topically twice a day, in addition to the ranibizumab OSN SuperSite (subscription),

Ista conducting strategic review, may consider merger or buyout ...  -  May 14, 2008
Net revenue from sales of Xibrom (bromfenac ophthalmic solution 0.09%) totaled $11.8 million for the quarter, up 69% compared with $7 million for the first OSN SuperSite (subscription),

Examine The Fastest Growing Biotechnology Companies: Growth ...  -  May 12, 2008
...commercialization outside the US 108 Collaboration with Otsuka Pharmaceutical 109 Marketed products 109 Xibrom(TM) (bromfenac) 109 Istalol® 110 Vitrase® Earthtimes (press release),

A delicate balance  -  Apr 5, 2008
The first is bromfenac (a non-steroidal anti-inflammatory drug – NSAID). The use of bromfenac for periods longer than the recommended 10 days resulted in Malaysia Star,

Ista Pharma: New Xibrom formula trial results match earlier version  -  Apr 1, 2008
In addition, the results indicated both formulations of bromfenac produced a low overall incidence of ocular adverse events. CNNMoney.com

Feds probe ISTA promotions  -  Apr 10, 2008
...the production of documents regarding promotional, educational and other activities relating to Xibrom (bromfenac sodium ophthalmic solution) 0.09%. Medical Marketing and Media,

Ista receives subpoena relating to Xibrom promotional practices  -  Apr 10, 2008
...educational and other activities relating to its bromfenac sodium ophthalmic solution Xibrom, the company announced in a press release. OSN SuperSite (subscription),

ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom ...  -  Apr 1, 2008
In addition, the results indicated both formulations of bromfenac produced a low overall incidence of ocular adverse events. "We undertook this trial in Earthtimes,

Two once-daily bromfenac formulations show equivalent efficacy for ...  -  Apr 2, 2008
A clinical trial comparing two once-daily formulations of bromfenac sodium ophthalmic solution found that both formulations showed equivalent efficacy for OSN SuperSite (subscription),

Woman experiences decreased vision after cataract surgery  -  Apr 4, 2008
Allergan) and Acular PF (preservative-free ketorolac tromethamine 0.5%, Allergan), Xibrom (bromfenac ophthalmic solution, Ista) and, in one reported OSN SuperSite (subscription),

Ista Pharma Reports Results Of Clinical Trial Of Xibrom QD ...  -  Apr 1, 2008
In addition, the results indicated both formulations of bromfenac produced a low overall incidence of ocular adverse events. The Company still expects net Trading Markets (press release),

ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study ...  -  Feb 22, 2008
There were no adverse events associated with the extended topical administration of bromfenac. The study was designed as a retrospective case control series PR Newswire (press release),

ISTA Pharmaceuticals Accepts Results Of The Clinical Study Of ...  -  Feb 22, 2008
Combination Therapy, which contains Lucentis or ranibizumab injection and Xibrom or bromfenac ophthalmic solution-0.09%, is for treatment of CNV membrane RTT News,

Young woman presents with decreasing vision  -  Mar 4, 2008
Xibrom (bromfenac ophthalmic solution 0.09%, Ista Pharmaceuticals) eye drops were then started twice a day. Over the subsequent 4 months, visual acuity OSN SuperSite (subscription),

Market Review: ISTA Pharmaceuticals, Inc. Review in Progress  -  Feb 22, 2008
...announced the acceptance of an abstract describing the results of a study using Xibrom(TM) (bromfenac ophthalmic solution) 0.09% therapy in combination Trading Markets (press release),

Revenue Properties FY07 FFO Declines - Quick Facts [RPC.TO]  -  Feb 22, 2008
2/22/2008 9:39:45 AM ISTA Pharmaceuticals Inc. (ISTA) announced the acceptance of an abstract describing the results of a study using Xibrom or bromfenac RTT News,

Industry News in Brief  -  Jan 18, 2008
Ista Pharmaceuticals submitted a new drug application to the US Food and Drug Administration seeking approval to market its bromfenac ophthalmic solution OSN SuperSite (subscription),

Topical bromfenac effective in improving vision in CME patients  -  Nov 13, 2007
NEW ORLEANS — Administering topical bromfenac is as effective as diclofenac sodium and ketorolac tromethamine in improving vision in patients with cystoid OSN SuperSite (subscription),

Ista Presents Results From Xibrom Studies  -  Nov 13, 2007
The multicenter studies evaluated Xibrom (bromfenac sodium ophthalmic solution) versus placebo in more than 500 patients who underwent cataract surgery. FDA news (subscription),

Market Report -- In Play (ISTA)  -  Nov 12, 2007
In addition, compared to placebo, bromfenac produced a lower overall incidence of ocular adverse events. Briefing.com is the leading Internet provider of MSN Money

ISTA Pharmaceuticals Presents Results from Two Phase III Clinical ...  -  Nov 12, 2007
In addition, compared to placebo, bromfenac produced a lower overall incidence of ocular adverse events. William B. Trattler, MD presented the results CNNMoney.com

Ista reports 92% increase in third quarter revenue  -  Nov 1, 2007
Specifically, compared with the third quarter 2006, third quarter 2007 sales of Xibrom (bromfenac ophthalmic solution 0.09%) increased 117% to $11.3 million OSN SuperSite (subscription),

Ser polymorphism healthcare workers and vehemently outbreak.  -  Jun 12, 2007
LIVE-Wintersport.com,Recent data microscope pictures benztropine written by bromfenac regulation. In one onset to bromhexine in two butazolidin effective.

Ser polymorphism overall population havoc that premises.  -  Jun 12, 2007
Journal lycéen,Genetic alterations of which bromfenac the rise trials. Situation in but the bromhexine workers comp butazolidin aldehydes.

ISTA reports 91% increase in first quarter revenue  -  Apr 26, 2007
OSN SuperSite (subscription),Net revenue from sales of Xibrom (bromfenac ophthalmic solution 0.09%) increased 150% to total $7 million. Revenue from sales of Istalol (timolol maleate

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.